Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3907620 | 0.92 | PKM (0.39) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 | |
| SCHEMBL3907440 | 0.92 | PKM (0.38) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 | |
| SCHEMBL3905192 | 0.92 | PKM (0.39) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 | |
| SCHEMBL5141084 | 0.91 | PKM (0.38) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 | |
| SCHEMBL3906270 | 0.91 | PKM (0.38) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 | |
| SCHEMBL3905637 | 0.91 | PKM (0.39) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 | |
| SCHEMBL3902390 | 0.91 | PKM (0.39) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 | |
| SCHEMBL3906127 | 0.90 | PKM (0.37) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 | |
| SCHEMBL3902393 | 0.90 | PKM (0.38) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 | |
| SCHEMBL3902413 | 0.90 | PKM (0.38) | CYP2C9ALDH1A1PKMLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-2018862-A1 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| EP-1973903-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | Speedel Experimenta AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007082907-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | REN, AGTR2, ACE | CYP2C9 158/4885ALDH1A1 1868/4885PKM 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.